Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity.

Setliff I, Shiakolas AR, Pilewski KA, Murji AA, Mapengo RE, Janowska K, Richardson S, Oosthuysen C, Raju N, Ronsard L, Kanekiyo M, Qin JS, Kramer KJ, Greenplate AR, McDonnell WJ, Graham BS, Connors M, Lingwood D, Acharya P, Morris L, Georgiev IS.

Cell. 2019 Nov 26. pii: S0092-8674(19)31224-3. doi: 10.1016/j.cell.2019.11.003. [Epub ahead of print]

PMID:
31787378
2.

Germline-Encoded Affinity for Cognate Antigen Enables Vaccine Amplification of a Human Broadly Neutralizing Response against Influenza Virus.

Sangesland M, Ronsard L, Kazer SW, Bals J, Boyoglu-Barnum S, Yousif AS, Barnes R, Feldman J, Quirindongo-Crespo M, McTamney PM, Rohrer D, Lonberg N, Chackerian B, Graham BS, Kanekiyo M, Shalek AK, Lingwood D.

Immunity. 2019 Oct 15;51(4):735-749.e8. doi: 10.1016/j.immuni.2019.09.001. Epub 2019 Sep 25.

PMID:
31563464
3.

Comparison of adjuvants to optimize influenza neutralizing antibody responses.

Rudicell RS, Garinot M, Kanekiyo M, Kamp HD, Swanson K, Chou TH, Dai S, Bedel O, Simard D, Gillespie RA, Yang K, Reardon M, Avila LZ, Besev M, Dhal PK, Dharanipragada R, Zheng L, Duan X, Dinapoli J, Vogel TU, Kleanthous H, Mascola JR, Graham BS, Haensler J, Wei CJ, Nabel GJ.

Vaccine. 2019 Sep 30;37(42):6208-6220. doi: 10.1016/j.vaccine.2019.08.030. Epub 2019 Sep 5.

PMID:
31493950
4.

Identification of prognostic factors to predict cognitive decline of patients with early Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative study.

Yagi T, Kanekiyo M, Ito J, Ihara R, Suzuki K, Iwata A, Iwatsubo T, Aoshima K; Alzheimer's Disease Neuroimaging Initiative; Japanese Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement (N Y). 2019 Aug 7;5:364-373. doi: 10.1016/j.trci.2019.06.004. eCollection 2019.

5.

Activation Dynamics and Immunoglobulin Evolution of Pre-existing and Newly Generated Human Memory B cell Responses to Influenza Hemagglutinin.

Andrews SF, Chambers MJ, Schramm CA, Plyler J, Raab JE, Kanekiyo M, Gillespie RA, Ransier A, Darko S, Hu J, Chen X, Yassine HM, Boyington JC, Crank MC, Chen GL, Coates E, Mascola JR, Douek DC, Graham BS, Ledgerwood JE, McDermott AB.

Immunity. 2019 Aug 20;51(2):398-410.e5. doi: 10.1016/j.immuni.2019.06.024. Epub 2019 Jul 23.

PMID:
31350180
6.

Author Correction: Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses.

Kanekiyo M, Joyce MG, Gillespie RA, Gallagher JR, Andrews SF, Yassine HM, Wheatley AK, Fisher BE, Ambrozak DR, Creanga A, Leung K, Yang ES, Boyoglu-Barnum S, Georgiev IS, Tsybovsky Y, Prabhakaran MS, Andersen H, Kong WP, Baxa U, Zephir KL, Ledgerwood JE, Koup RA, Kwong PD, Harris AK, McDermott AB, Mascola JR, Graham BS.

Nat Immunol. 2019 Jun;20(6):765. doi: 10.1038/s41590-019-0395-0.

PMID:
30980067
7.

Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells.

Bu W, Joyce MG, Nguyen H, Banh DV, Aguilar F, Tariq Z, Yap ML, Tsujimura Y, Gillespie RA, Tsybovsky Y, Andrews SF, Narpala SR, McDermott AB, Rossmann MG, Yasutomi Y, Nabel GJ, Kanekiyo M, Cohen JI.

Immunity. 2019 May 21;50(5):1305-1316.e6. doi: 10.1016/j.immuni.2019.03.010. Epub 2019 Apr 9.

PMID:
30979688
8.

Epitope-Specific Serological Assays for RSV: Conformation Matters.

Phung E, Chang LA, Morabito KM, Kanekiyo M, Chen M, Nair D, Kumar A, Chen GL, Ledgerwood JE, Graham BS, Ruckwardt TJ.

Vaccines (Basel). 2019 Feb 23;7(1). pii: E23. doi: 10.3390/vaccines7010023.

9.

Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages.

Corbett KS, Moin SM, Yassine HM, Cagigi A, Kanekiyo M, Boyoglu-Barnum S, Myers SI, Tsybovsky Y, Wheatley AK, Schramm CA, Gillespie RA, Shi W, Wang L, Zhang Y, Andrews SF, Joyce MG, Crank MC, Douek DC, McDermott AB, Mascola JR, Graham BS, Boyington JC.

MBio. 2019 Feb 26;10(1). pii: e02810-18. doi: 10.1128/mBio.02810-18.

10.

Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses.

Kanekiyo M, Joyce MG, Gillespie RA, Gallagher JR, Andrews SF, Yassine HM, Wheatley AK, Fisher BE, Ambrozak DR, Creanga A, Leung K, Yang ES, Boyoglu-Barnum S, Georgiev IS, Tsybovsky Y, Prabhakaran MS, Andersen H, Kong WP, Baxa U, Zephir KL, Ledgerwood JE, Koup RA, Kwong PD, Harris AK, McDermott AB, Mascola JR, Graham BS.

Nat Immunol. 2019 Mar;20(3):362-372. doi: 10.1038/s41590-018-0305-x. Epub 2019 Feb 11. Erratum in: Nat Immunol. 2019 Apr 12;:.

11.

New Vaccine Design and Delivery Technologies.

Kanekiyo M, Ellis D, King NP.

J Infect Dis. 2019 Apr 8;219(Supplement_1):S88-S96. doi: 10.1093/infdis/jiy745.

PMID:
30715361
12.

Author Correction: A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite.

Kisalu NK, Idris AH, Weidle C, Flores-Garcia Y, Flynn BJ, Sack BK, Murphy S, Schön A, Freire E, Francica JR, Miller AB, Gregory J, March S, Liao HX, Haynes BF, Wiehe K, Trama AM, Saunders KO, Gladden MA, Monroe A, Bonsignori M, Kanekiyo M, Wheatley AK, McDermott AB, Farney SK, Chuang GY, Zhang B, Kc N, Chakravarty S, Kwong PD, Sinnis P, Bhatia SN, Kappe SHI, Sim BKL, Hoffman SL, Zavala F, Pancera M, Seder RA.

Nat Med. 2019 Jan;25(1):188-189. doi: 10.1038/s41591-018-0315-0.

PMID:
30552419
13.

A unique nanoparticulate TLR9 agonist enables a HA split vaccine to confer FcγR-mediated protection against heterologous lethal influenza virus infection.

Yamamoto T, Masuta Y, Momota M, Kanekiyo M, Kanuma T, Takahama S, Moriishi E, Yasutomi Y, Saito T, Graham BS, Takahashi Y, Ishii KJ.

Int Immunol. 2019 Feb 15;31(2):81-90. doi: 10.1093/intimm/dxy069.

14.

A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite.

Kisalu NK, Idris AH, Weidle C, Flores-Garcia Y, Flynn BJ, Sack BK, Murphy S, Schön A, Freire E, Francica JR, Miller AB, Gregory J, March S, Liao HX, Haynes BF, Wiehe K, Trama AM, Saunders KO, Gladden MA, Monroe A, Bonsignori M, Kanekiyo M, Wheatley AK, McDermott AB, Farney SK, Chuang GY, Zhang B, Kc N, Chakravarty S, Kwong PD, Sinnis P, Bhatia SN, Kappe SHI, Sim BKL, Hoffman SL, Zavala F, Pancera M, Seder RA.

Nat Med. 2018 May;24(4):408-416. doi: 10.1038/nm.4512. Epub 2018 Mar 19. Erratum in: Nat Med. 2019 Jan;25(1):188-189.

15.

Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape.

Wang L, Shi W, Chappell JD, Joyce MG, Zhang Y, Kanekiyo M, Becker MM, van Doremalen N, Fischer R, Wang N, Corbett KS, Choe M, Mason RD, Van Galen JG, Zhou T, Saunders KO, Tatti KM, Haynes LM, Kwong PD, Modjarrad K, Kong WP, McLellan JS, Denison MR, Munster VJ, Mascola JR, Graham BS.

J Virol. 2018 Apr 27;92(10). pii: e02002-17. doi: 10.1128/JVI.02002-17. Print 2018 May 15.

16.

Two-Component Ferritin Nanoparticles for Multimerization of Diverse Trimeric Antigens.

Georgiev IS, Joyce MG, Chen RE, Leung K, McKee K, Druz A, Van Galen JG, Kanekiyo M, Tsybovsky Y, Yang ES, Yang Y, Acharya P, Pancera M, Thomas PV, Wanninger T, Yassine HM, Baxa U, Doria-Rose NA, Cheng C, Graham BS, Mascola JR, Kwong PD.

ACS Infect Dis. 2018 May 11;4(5):788-796. doi: 10.1021/acsinfecdis.7b00192. Epub 2018 Mar 6.

PMID:
29451984
17.

Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein.

Tian D, Battles MB, Moin SM, Chen M, Modjarrad K, Kumar A, Kanekiyo M, Graepel KW, Taher NM, Hotard AL, Moore ML, Zhao M, Zheng ZZ, Xia NS, McLellan JS, Graham BS.

Nat Commun. 2017 Nov 30;8(1):1877. doi: 10.1038/s41467-017-01858-w.

18.

Corrigendum: Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state.

Rossey I, Gilman MSA, Kabeche SC, Sedeyn K, Wrapp D, Kanekiyo M, Chen M, Mas V, Spitaels J, Melero JA, Graham BS, Schepens B, McLellan JS, Saelens X.

Nat Commun. 2017 Nov 29;8:16165. doi: 10.1038/ncomms16165.

19.

Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans.

Andrews SF, Joyce MG, Chambers MJ, Gillespie RA, Kanekiyo M, Leung K, Yang ES, Tsybovsky Y, Wheatley AK, Crank MC, Boyington JC, Prabhakaran MS, Narpala SR, Chen X, Bailer RT, Chen G, Coates E, Kwong PD, Koup RA, Mascola JR, Graham BS, Ledgerwood JE, McDermott AB.

Sci Immunol. 2017 Jul 14;2(13). pii: eaan2676. doi: 10.1126/sciimmunol.aan2676.

PMID:
28783708
20.

Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state.

Rossey I, Gilman MS, Kabeche SC, Sedeyn K, Wrapp D, Kanekiyo M, Chen M, Mas V, Spitaels J, Melero JA, Graham BS, Schepens B, McLellan JS, Saelens X.

Nat Commun. 2017 Feb 13;8:14158. doi: 10.1038/ncomms14158. Erratum in: Nat Commun. 2017 Nov 29;8:16165.

21.

Reconstituted B cell receptor signaling reveals carbohydrate-dependent mode of activation.

Villar RF, Patel J, Weaver GC, Kanekiyo M, Wheatley AK, Yassine HM, Costello CE, Chandler KB, McTamney PM, Nabel GJ, McDermott AB, Mascola JR, Carr SA, Lingwood D.

Sci Rep. 2016 Oct 31;6:36298. doi: 10.1038/srep36298.

22.

Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus.

Killikelly AM, Kanekiyo M, Graham BS.

Sci Rep. 2016 Sep 29;6:34108. doi: 10.1038/srep34108.

23.

Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses.

Joyce MG, Wheatley AK, Thomas PV, Chuang GY, Soto C, Bailer RT, Druz A, Georgiev IS, Gillespie RA, Kanekiyo M, Kong WP, Leung K, Narpala SN, Prabhakaran MS, Yang ES, Zhang B, Zhang Y, Asokan M, Boyington JC, Bylund T, Darko S, Lees CR, Ransier A, Shen CH, Wang L, Whittle JR, Wu X, Yassine HM, Santos C, Matsuoka Y, Tsybovsky Y, Baxa U; NISC Comparative Sequencing Program, Mullikin JC, Subbarao K, Douek DC, Graham BS, Koup RA, Ledgerwood JE, Roederer M, Shapiro L, Kwong PD, Mascola JR, McDermott AB.

Cell. 2016 Jul 28;166(3):609-623. doi: 10.1016/j.cell.2016.06.043. Epub 2016 Jul 21.

24.

A rationally engineered yeast pyruvyltransferase Pvg1p introduces sialylation-like properties in neo-human-type complex oligosaccharide.

Higuchi Y, Yoshinaga S, Yoritsune K, Tateno H, Hirabayashi J, Nakakita S, Kanekiyo M, Kakuta Y, Takegawa K.

Sci Rep. 2016 May 19;6:26349. doi: 10.1038/srep26349.

25.

Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody.

Corti D, Misasi J, Mulangu S, Stanley DA, Kanekiyo M, Wollen S, Ploquin A, Doria-Rose NA, Staupe RP, Bailey M, Shi W, Choe M, Marcus H, Thompson EA, Cagigi A, Silacci C, Fernandez-Rodriguez B, Perez L, Sallusto F, Vanzetta F, Agatic G, Cameroni E, Kisalu N, Gordon I, Ledgerwood JE, Mascola JR, Graham BS, Muyembe-Tamfun JJ, Trefry JC, Lanzavecchia A, Sullivan NJ.

Science. 2016 Mar 18;351(6279):1339-42. doi: 10.1126/science.aad5224. Epub 2016 Feb 25.

26.

Structural and molecular basis for Ebola virus neutralization by protective human antibodies.

Misasi J, Gilman MS, Kanekiyo M, Gui M, Cagigi A, Mulangu S, Corti D, Ledgerwood JE, Lanzavecchia A, Cunningham J, Muyembe-Tamfun JJ, Baxa U, Graham BS, Xiang Y, Sullivan NJ, McLellan JS.

Science. 2016 Mar 18;351(6279):1343-6. doi: 10.1126/science.aad6117. Epub 2016 Feb 25.

27.

In vitro reconstitution of B cell receptor-antigen interactions to evaluate potential vaccine candidates.

Weaver GC, Villar RF, Kanekiyo M, Nabel GJ, Mascola JR, Lingwood D.

Nat Protoc. 2016 Feb;11(2):193-213. doi: 10.1038/nprot.2016.009. Epub 2016 Jan 7.

PMID:
26741406
28.

Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera.

Ngwuta JO, Chen M, Modjarrad K, Joyce MG, Kanekiyo M, Kumar A, Yassine HM, Moin SM, Killikelly AM, Chuang GY, Druz A, Georgiev IS, Rundlet EJ, Sastry M, Stewart-Jones GB, Yang Y, Zhang B, Nason MC, Capella C, Peeples ME, Ledgerwood JE, McLellan JS, Kwong PD, Graham BS.

Sci Transl Med. 2015 Oct 14;7(309):309ra162. doi: 10.1126/scitranslmed.aac4241.

29.

Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection.

Yassine HM, Boyington JC, McTamney PM, Wei CJ, Kanekiyo M, Kong WP, Gallagher JR, Wang L, Zhang Y, Joyce MG, Lingwood D, Moin SM, Andersen H, Okuno Y, Rao SS, Harris AK, Kwong PD, Mascola JR, Nabel GJ, Graham BS.

Nat Med. 2015 Sep;21(9):1065-70. doi: 10.1038/nm.3927. Epub 2015 Aug 24.

PMID:
26301691
30.

Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site.

Kanekiyo M, Bu W, Joyce MG, Meng G, Whittle JR, Baxa U, Yamamoto T, Narpala S, Todd JP, Rao SS, McDermott AB, Koup RA, Rossmann MG, Mascola JR, Graham BS, Cohen JI, Nabel GJ.

Cell. 2015 Aug 27;162(5):1090-100. doi: 10.1016/j.cell.2015.07.043. Epub 2015 Aug 13.

31.

Evaluation of candidate vaccine approaches for MERS-CoV.

Wang L, Shi W, Joyce MG, Modjarrad K, Zhang Y, Leung K, Lees CR, Zhou T, Yassine HM, Kanekiyo M, Yang ZY, Chen X, Becker MM, Freeman M, Vogel L, Johnson JC, Olinger G, Todd JP, Bagci U, Solomon J, Mollura DJ, Hensley L, Jahrling P, Denison MR, Rao SS, Subbarao K, Kwong PD, Mascola JR, Kong WP, Graham BS.

Nat Commun. 2015 Jul 28;6:7712. doi: 10.1038/ncomms8712.

32.

H5N1 Vaccine-Elicited Memory B Cells Are Genetically Constrained by the IGHV Locus in the Recognition of a Neutralizing Epitope in the Hemagglutinin Stem.

Wheatley AK, Whittle JR, Lingwood D, Kanekiyo M, Yassine HM, Ma SS, Narpala SR, Prabhakaran MS, Matus-Nicodemos RA, Bailer RT, Nabel GJ, Graham BS, Ledgerwood JE, Koup RA, McDermott AB.

J Immunol. 2015 Jul 15;195(2):602-10. doi: 10.4049/jimmunol.1402835. Epub 2015 Jun 15.

33.

Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages.

Whittle JR, Wheatley AK, Wu L, Lingwood D, Kanekiyo M, Ma SS, Narpala SR, Yassine HM, Frank GM, Yewdell JW, Ledgerwood JE, Wei CJ, McDermott AB, Graham BS, Koup RA, Nabel GJ.

J Virol. 2014 Apr;88(8):4047-57. doi: 10.1128/JVI.03422-13. Epub 2014 Feb 5.

34.

Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies.

Kanekiyo M, Wei CJ, Yassine HM, McTamney PM, Boyington JC, Whittle JR, Rao SS, Kong WP, Wang L, Nabel GJ.

Nature. 2013 Jul 4;499(7456):102-6. doi: 10.1038/nature12202. Epub 2013 May 22.

PMID:
23698367
35.

Outer domain of HIV-1 gp120: antigenic optimization, structural malleability, and crystal structure with antibody VRC-PG04.

Joyce MG, Kanekiyo M, Xu L, Biertümpfel C, Boyington JC, Moquin S, Shi W, Wu X, Yang Y, Yang ZY, Zhang B, Zheng A, Zhou T, Zhu J, Mascola JR, Kwong PD, Nabel GJ.

J Virol. 2013 Feb;87(4):2294-306. doi: 10.1128/JVI.02717-12. Epub 2012 Dec 12.

36.

Intradermal delivery of recombinant vaccinia virus vector DIs induces gut-mucosal immunity.

Yoshino N, Kanekiyo M, Hagiwara Y, Okamura T, Someya K, Matsuo K, Ami Y, Sato S, Yamamoto N, Honda M.

Scand J Immunol. 2010 Aug;72(2):98-105. doi: 10.1111/j.1365-3083.2010.02416.x.

37.

Different vaccine vectors delivering the same antigen elicit CD8+ T cell responses with distinct clonotype and epitope specificity.

Honda M, Wang R, Kong WP, Kanekiyo M, Akahata W, Xu L, Matsuo K, Natarajan K, Robinson H, Asher TE, Price DA, Douek DC, Margulies DH, Nabel GJ.

J Immunol. 2009 Aug 15;183(4):2425-34. doi: 10.4049/jimmunol.0900581. Epub 2009 Jul 20.

38.

Delivery of human immunodeficiency virus vaccine vectors to the intestine induces enhanced mucosal cellular immunity.

Wang L, Cheng C, Ko SY, Kong WP, Kanekiyo M, Einfeld D, Schwartz RM, King CR, Gall JG, Nabel GJ.

J Virol. 2009 Jul;83(14):7166-75. doi: 10.1128/JVI.00374-09. Epub 2009 May 6.

39.

Enhanced induction of intestinal cellular immunity by oral priming with enteric adenovirus 41 vectors.

Ko SY, Cheng C, Kong WP, Wang L, Kanekiyo M, Einfeld D, King CR, Gall JG, Nabel GJ.

J Virol. 2009 Jan;83(2):748-56. doi: 10.1128/JVI.01811-08. Epub 2008 Nov 5.

40.

Mucosal administration of completely non-replicative vaccinia virus recombinant Dairen I strain elicits effective mucosal and systemic immunity.

Yoshino N, Kanekiyo M, Hagiwara Y, Okamura T, Someya K, Matsuo K, Ami Y, Sato S, Yamamoto N, Honda M.

Scand J Immunol. 2008 Nov;68(5):476-83. doi: 10.1111/j.1365-3083.2008.02168.x. Epub 2008 Sep 18.

41.

A novel CD4-conjugated ultraviolet light-activated photocatalyst inactivates HIV-1 and SIV efficiently.

Yamaguchi K, Sugiyama T, Kato S, Kondo Y, Ageyama N, Kanekiyo M, Iwata M, Koyanagi Y, Yamamoto N, Honda M.

J Med Virol. 2008 Aug;80(8):1322-31. doi: 10.1002/jmv.21235.

PMID:
18551617
42.
43.

Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity.

Ami Y, Izumi Y, Matsuo K, Someya K, Kanekiyo M, Horibata S, Yoshino N, Sakai K, Shinohara K, Matsumoto S, Yamada T, Yamazaki S, Yamamoto N, Honda M.

J Virol. 2005 Oct;79(20):12871-9. Erratum in: J Virol. 2006 Oct;80(20):10288.

44.

Reduced bactericidal activity and nitric oxide production in metallothionein-deficient macrophages in response to lipopolysaccharide stimulation.

Itoh N, Shibayama H, Kanekiyo M, Namphung D, Nakanishi T, Matsuyama A, Odani T, Tanaka K.

Toxicology. 2005 Dec 15;216(2-3):188-96. Epub 2005 Sep 12.

PMID:
16157437
45.

Mycobacterial codon optimization enhances antigen expression and virus-specific immune responses in recombinant Mycobacterium bovis bacille Calmette-Guérin expressing human immunodeficiency virus type 1 Gag.

Kanekiyo M, Matsuo K, Hamatake M, Hamano T, Ohsu T, Matsumoto S, Yamada T, Yamazaki S, Hasegawa A, Yamamoto N, Honda M.

J Virol. 2005 Jul;79(14):8716-23.

46.

Metallothionein is required for zinc-induced expression of the macrophage colony stimulating factor gene.

Kanekiyo M, Itoh N, Kawasaki A, Matsuda K, Nakanishi T, Tanaka K.

J Cell Biochem. 2002;86(1):145-53.

PMID:
12112025
47.

Metallothionein modulates lipopolysaccharide-stimulated tumour necrosis factor expression in mouse peritoneal macrophages.

Kanekiyo M, Itoh N, Kawasaki A, Matsuyama A, Matsuda K, Nakanishi T, Tanaka K.

Biochem J. 2002 Jan 15;361(Pt 2):363-9.

48.

Zinc-induced activation of the human cytomegalovirus major immediate-early promoter is mediated by metallothionein and nuclear factor-kappaB.

Kanekiyo M, Itoh N, Kawasaki A, Tanaka J, Nakanishi T, Tanaka K.

Toxicol Appl Pharmacol. 2001 Jun 15;173(3):146-53.

PMID:
11437636
49.

Cellular zinc status regulates cytomegalovirus major immediate-early promoter.

Kanekiyo M, Itoh N, Mano M, Kawasaki A, Tanaka J, Muto N, Tanaka K.

Antiviral Res. 2000 Sep;47(3):207-14.

PMID:
10974373
50.

Two metallothioneins in the fresh-water fish, crucian carp (Carassius cuvieri): cDNA cloning and assignment of their expression isoforms.

Ren HW, Itoh N, Kanekiyo M, Tominaga S, Kohroki J, Hwang GS, Nakanishi T, Muto N, Tanaka K.

Biol Pharm Bull. 2000 Feb;23(2):145-8.

PMID:
10706375

Supplemental Content

Loading ...
Support Center